Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

Anemia Clinical Trial

— FO2RWARD-2  

Official title:

Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (FO2RWARD-2)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03799627
• Other study ID #: AKB-6548-CI-0025
• Status: Completed
• Phase: Phase 2
• Start date: January 31, 2019
• Est. completion date: July 15, 2020

Study information

• Verified date: September 2022
• Source: Akebia Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2 open-label efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) study to evaluate oral Vadadustat for the treatment of anemia in hemodialysis participants converting from Epoetin Alfa therapy.

Description:

This is a Phase 2, randomized, open-label study to evaluate efficacy and safety of oral Vadadustat for the treatment of anemia in hemodialysis participants converting from Epoetin Alfa therapy. The study will be conducted in two parts running in parallel: Part 1, Main Study in a hemodialysis population on maintenance treatment with Epoetin Alfa; Part 2 is in a hemodialysis population that are erythropoiesis-stimulating agent (ESA) hyporesponders on maintenance treatment with Epoetin Alfa. For all participants (Main and ESA hyporesponder parallel study), the study will include a Screening Period, a Treatment Period, and a Safety Follow-Up Period. PK and PD sampling will be done throughout the study. The aim is to achieve and maintain hemoglobin (Hb) levels within the target range of 10.0 to 11.0 grams per deciliter (g/dL), inclusive, while targeting the middle of the range and minimizing excursions outside the target range.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 175
• Est. completion date: July 15, 2020
• Est. primary completion date: June 5, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• =18 years of age, providing informed consent

• Receiving chronic, outpatient in-center hemodialysis (TIW) for end-stage renal disease for at least 12 weeks prior to Screening

• Maintained on intravenous Epoetin Alfa therapy for 8 weeks prior to and including Screening through Screening Visit 2 (SV2)

• Eligibility in the Main study and erythropoiesis-stimulating agent (ESA) hyporesponder parallel study is based on the following mean weekly Epoetin Alfa doses:

1. Main study: Mean weekly Epoetin Alfa dose <300 Units per kilogram per week (U/kg/week) for 8 weeks prior to SV2;

2. ESA hyporesponder parallel study: Mean weekly Epoetin Alfa dose =300 U/kg/week for 8 weeks prior to SV2

• Two Hb values measured by the central laboratory at least 4 days apart between Screening Visit 1 (SV1) and SV2 as indicated:.

1. Main study: 2 Hb values between 8.5 and 11.0 g/dL, inclusive;

2. ESA hyporesponder parallel study: 2 Hb values between 8.0 and 10.0 grams per deciliter (g/dL), inclusive

• Serum ferritin =100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) =20% during Screening

• Folate and vitamin B12 measurements = lower limit of normal during Screening

• Hemodialysis adequacy as indicated by single-pool Kt/Vurea =1.2 using the most recent historical measurement within 8 weeks prior to or during Screening

• Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure

Exclusion Criteria:

• Anemia due to a cause other than chronic kidney disease (e.g., sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia)

• Active bleeding or recent blood loss within 8 weeks prior to randomization

• Red blood cell (RBC) transfusion within 8 weeks prior to randomization

• Anticipated to discontinue hemodialysis during the study

• Judged by the Investigator that the participant is likely to need rescue therapy (ESA administration or RBC transfusion) immediately after enrollment in the study

• History of chronic liver disease (e.g., chronic infectious hepatitis, chronic autoimmune liver disease, cirrhosis or fibrosis of the liver)

• Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT), alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT), or total bilirubin >1.5 x upper limit of normal (ULN) during Screening. Participants with a history of Gilbert's syndrome are not excluded.

• Current uncontrolled hypertension as determined by the Investigator that would contraindicate the use of Epoetin Alfa

• Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure (HF) or New York Heart Association Class IV HF, or stroke within 12 weeks prior to or during Screening

• History of new or recurrent malignancy within 2 years prior to and during Screening or currently receiving treatment or suppressive therapy for cancer. Participants with treated basal cell carcinoma of skin, curatively resected squamous cell carcinoma of skin, or cervical carcinoma in situ are not excluded.

• History of deep vein thrombosis or pulmonary embolism within 12 weeks prior to or during Screening

• History of hemosiderosis or hemochromatosis

• History of prior organ transplantation (participants with a history of failed kidney transplant or corneal transplants are not excluded)

• Scheduled organ transplant from a living donor and participants on the kidney transplant wait-list who are expected to receive a transplant within 6 months

• History of a prior hematopoietic stem cell or bone marrow transplant (stem cell therapy for knee arthritis is not excluded)

• Known hypersensitivity to Vadadustat, Epoetin Alfa, or any of their excipients

• Any prior use of a hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitor or any use of an investigational medication within 30 days or 5 half-lives of the investigational medication (whichever is longer), prior to randomization

• For female participants of non-childbearing potential:

1. inability to confirm surgical sterility (e.g., hysterectomy, bilateral tubal ligation, bilateral oophorectomy) at least 1 month prior to Screening;

2. not considered post-menopausal (no menses for >1 year with follicle stimulating hormone >40 U/Liter at Screening)

• For female participants of childbearing potential:

1. lack of confirmation of the use of acceptable forms of contraception* for a minimum of one complete menstrual cycle prior to Screening;

2. positive serum pregnancy test at SV2;

3. unwilling to use two acceptable forms of contraception* (at least one of which must be a barrier method) starting Baseline/Day 1, throughout the Treatment Period and for 30 days after the final study drug administration

• Breastfeeding during Screening or throughout the Treatment Period and for 30 days after the final study drug administration

• Donation of ova starting at Screening, throughout the Treatment Period, and for 30 days after the final study drug administration

• Male participants who have not had a vasectomy and do not agree to the following: use of an acceptable form of contraception* during the study and for 30 days after the last dose of the study drug; to not donate semen during the study and for at least 30 days after the last dose of Vadadustat

• Participants with bilateral native nephrectomy

• Any other reason, which in the opinion of the Investigator, would make the participant not suitable for participation in the study

• Acceptable forms of contraception include:

• Established use of oral, injected or implanted hormonal methods of contraception;

• Placement of an intrauterine device or intrauterine system;

• Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

Related Conditions & MeSH terms

• Anemia
• Dialysis-dependent Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• Vadadustat
Vadadustat Tablets 150 mg
• Epoetin Alfa
Epoetin Alfa
• Vadadustat TIW
Oral Vadadustat

Locations

Country	Name	City	State
United States	Research Site	Asheville	North Carolina
United States	Research Site	Augusta	Georgia
United States	Research Site	Bridgeport	Connecticut
United States	Research Site	Bronx	New York
United States	Research Site	Canton	Ohio
United States	Research Site	Chesapeake	Virginia
United States	Research Site	Coral Gables	Florida
United States	Research Site	Denver	Colorado
United States	Research Site	El Paso	Texas
United States	Research Site	Fresno	California
United States	Research Site	Granada Hills	California
United States	Research Site	Hartford	Connecticut
United States	Research Site	Hollywood	Florida
United States	Research Site	Houston	Texas
United States	Research Site	Kansas City	Missouri
United States	Research Site	Las Vegas	Nevada
United States	Research Site	Los Angeles	California
United States	Research Site	Miami	Florida
United States	Research Site	Miami	Florida
United States	Research Site	Miami	Florida
United States	Research Site #1	Minneapolis	Minnesota
United States	Research Site #2	Minneapolis	Minnesota
United States	Research Site	Norfolk	Virginia
United States	Research Site	Northridge	California
United States	Research Site	Oklahoma City	Oklahoma
United States	Research Site	Riverside	California
United States	Research Site	Roseville	Michigan
United States	Research Site	San Antonio	Texas
United States	Research Site	San Antonio	Texas
United States	Research Site #1	San Dimas	California
United States	Research Site #2	San Dimas	California
United States	Research Site	San Gabriel	California
United States	Research Site	Statesboro	Georgia
United States	Research Site	Tampa	Florida
United States	Research Site	Tampa	Florida
United States	Research Site	Tarzana	California
United States	Research Site	Vacaville	California
United States	Research Site	Victorville	California
United States	Research Site	Wauwatosa	Wisconsin
United States	Research Site	Wilmington	North Carolina
United States	Research Site	Winter Park	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Akebia Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP)	Change from Baseline in Hb value was calculated as the PEP Hb value minus the Baseline Hb value. The PEP value was the average Hb value from Week 10 to Week 12. The Baseline Hb value was defined as the average of the final two Hb values prior to start of dosing on Day 1.	Baseline; Week 10 to Week 12
Primary	Number of Participants With Treatment-emergent Adverse Events (TEAEs)	An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. An AE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. TEAEs, defined as AEs that began (or pre-existing AEs that worsened) on or after the first dose through each participant's last participation date, are reported.	Up to Week 24
Primary	Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values	Parameters assessed for laboratory values included hematology (excluding the primary and secondary efficacy endpoint results related to Hb), clinical chemistry, lipid profiles, and glucose. The investigator was responsible for reviewing laboratory results for clinically significant changes.	Up to Week 24
Primary	Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values	Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing vital sign values for clinically significant changes.	Up to Week 24
Primary	Number of Participants Classified as Hb Outliers	The target range for Hb was from 10.0 to 11.0 grams per deciliter (g/dL). Hb outliers included participants with a Hb increase of more than 12.0 g/dL or <8.0 g/dL and decline in Hb =0.5 g/dL from Baseline, and a Hb increase to more than 1.0 g/dL within any 2-week interval during the Study Period.	Weeks 13 - 20
Secondary	Number of Participants With Hb Values Within the Target Range at the PEP	The target range for Hb was from 10.0 to 11.0 g/dL, inclusive. The PEP was comprised of Week 10 to Week 12.	Week 10 to Week 12
Secondary	Mean Change in Hb From the PEP to the Secondary Evaluation Period (SEP) in Participants Who Transitioned to Three Times Per Week (TIW) Vadadustat Dosing After Week 12	Change from PEP was calculated as the SEP value minus the PEP value. The PEP value was the average Hb value from Week 10 to Week 12. The SEP value was the average Hb value from Week 18 to Week 20. For the Main Study, analysis is presented per dose level according to the starting dose in TIW regimen, as well as being presented as a combined arm for "Vadadustat Total (TIW dosing regimen)". For the ESA Hyporesponder Parallel Study, a starting dose classification for TIW dosing regimen was not applicable due to no participants switching from Vadadustat QD to TIW dosing.	Week 10 to Week 12; Week 18 to Week 20
Secondary	Mean Change in Hb Between Baseline and the SEP	Change from Baseline was calculated as the SEP value minus the Baseline value. The Baseline Hb value was defined as the average of the final two Hb values prior to start of dosing on Day 1. The SEP value was the average Hb value from Week 18 to Week 20.	Baseline; Week 18 to Week 20
Secondary	Number of Participants With Hb Values Within the Target Range at the SEP	The target range for Hb was from 10.0 to 11.0 g/dL. The SEP was comprised of Week 18 to Week 20.	Week 18 to Week 20
Secondary	Number of Participants With Hb Values Within the Target Range at the SEP in Participants Who Transitioned to TIW Vadadustat Dosing	The target range for Hb was from 10.0 to 11.0 g/dL. The SEP was comprised of Week 18 to Week 20. For the Main Study, analysis is presented per dose level according to the starting dose in TIW regimen, as well as being presented as a combined arm for "Vadadustat Total (TIW dosing regimen)". For the ESA Hyporesponder Parallel Study, a starting dose classification for TIW dosing regimen was not applicable due to no participants switching from Vadadustat QD to TIW dosing.	Week 18 to Week 20
Secondary	Number of Participants With a Mean Increase in Hb From Baseline to the PEP =0.5 g/dL or With Hb Values Within the Target Range at the PEP	The target range for Hb was from 10.0 to 11.0 g/dL. The PEP was comprised of Week 10 to Week 12.	Week 10 to Week 12
Secondary	Number of Participants With a Mean Increase in Hb From Baseline to the SEP =0.5 g/dL or With Hb Values Within the Target Range at the SEP	The target range for Hb was from 10.0 to 11.0 grams per g/dL. The SEP was comprised of Week 18 to Week 20.	Week 18 to Week 20
Secondary	Number of Participants Requiring at Least One Intravenous (IV) Elemental Iron Supplementation	Iron supplementation was performed to maintain ferritin =200 nanograms/milliliters (ng/mL) and transferrin saturation (TSAT) =20%.	Up to Week 20
Secondary	Number of Participants Requiring Erythropoiesis-stimulating Agent (ESA) Rescue	ESA rescue therapy was administered in participants with Hb =8.5 g/dL, and was stopped when Hb reached =9.0 g/dL.	Up to Week 20
Secondary	Number of Participants Requiring Red Blood Cell (RBC) Transfusion	RBC transfusion was administered as rescue therapy in the event of an acute or severe loss of blood.	Up to Week 20
Secondary	Mean Serum Concentration of Erythropoietin (EPO) for Vadadustat Treatment Groups by Strata of Epoetin Alfa Dose Group	Blood samples were collected from participants at defined time points for the assessment of EPO concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.	Baseline; Week 1 (pre-dose), Week 1 +1 (Day 8; pre-dose), Week 11 (pre-dose), and Week 13 (pre-dose)
Secondary	Mean Change From Baseline in Reticulocyte Count	Blood samples were collected from participants at defined time points for the assessment of reticulocyte count. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.	Baseline; Week 1, Week 4, Week 8, Week 11, Week 12, Week 13, Week 16, and Week 20
Secondary	Mean Change From Baseline in Iron Concentration	Blood samples were collected from participants at defined time points for the assessment of iron indices, including iron concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.	Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20
Secondary	Mean Change From Baseline in Ferritin Concentration	Blood samples were collected from participants at defined time points for the assessment of iron indices, including ferritin concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.	Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20
Secondary	Mean Change From Baseline in Total Iron Binding Capacity	Blood samples were collected from participants at defined time points for the assessment of iron indices, including Total Iron Binding Capacity. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.	Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20
Secondary	Mean Change From Baseline in Hepcidin Concentration	Blood samples were collected from participants at defined time points for the assessment of hepcidin concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.	Baseline; Week 12 and Week 20
Secondary	Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Vadadustat Following a Single Dose	Blood samples were collected from participants at defined time points for the assessment of Cmax of Vadadustat following a single dose.	Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Secondary	Geometric Mean Area Under the Concentration-time Curve (AUC) From Time 0 to 24 Hours (AUC0-24) of Vadadustat Following a Single Dose	Blood samples were collected from participants at defined time points for the assessment of AUC and AUC0-24 of Vadadustat following a single dose.	Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Secondary	Median Terminal Half-life (t1/2) of Vadadustat Following a Single Dose	Blood samples were collected from participants at defined time points for the assessment of t1/2 of Vadadustat following a single dose.	Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Secondary	Median Time to Reach Cmax (Tmax) of Vadadustat Following a Single Dose	Blood samples were collected from participants at defined time points for the assessment of Tmax of Vadadustat following a single dose.	Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Secondary	Geometric Mean Elimination Rate Constant (?z) of Vadadustat Following a Single Dose	Blood samples were collected from participants at defined time points for the assessment of ?z of Vadadustat following a single dose.	Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Secondary	Geometric Mean Apparent Total Body Clearance (CLss/F) of Vadadustat Following a Single Dose	Blood samples were collected from participants at defined time points for the assessment of CLss/F of Vadadustat following a single dose.	Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Secondary	Geometric Mean Apparent Volume of Distribution (Vz/F) of Vadadustat Following a Single Dose	Blood samples were collected from participants at defined time points for the assessment of Vz/F of Vadadustat following a single dose.	Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose